Inhibition of cholesterol synthesis by atorvastatin in homozygous familial hypercholesterolaemia.

No abstract is available for this paper.

• Publication year

  2000

• Venue

  Atherosclerosis

• Publication date

  2000-06-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/S0021-9150(99)00435-9PMID 10856535
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Development and validation of a high-performance liquid chromatography tandem mass spectrometry assay for atorvastatin, ortho-hydroxy atorvastatin, and para-hydroxy atorvastatin in human, dog, and rat plasma

  1999cited by this paper
• An MTP inhibitor that normalizes atherogenic lipoprotein levels in WHHL rabbits.

  1998cited by this paper
• The ACAT inhibitor, CI-1011 is effective in the prevention and regression of aortic fatty streak area in hamsters.

  1998cited by this paper
• Expanded-dose simvastatin is effective in homozygous familial hypercholesterolaemia.

  1997cited by this paper
• Decreased production of low density lipoprotein by atorvastatin after apheresis in homozygous familial hypercholesterolemia.

  1997cited by this paper
• Plasma mevalonic acid, an index of cholesterol synthesis in vivo, and responsiveness to HMG-CoA reductase inhibitors in familial hypercholesterolaemia.

  1996cited by this paper
• Role of cholesterol in regulating apolipoprotein B secretion by the liver.

  1996cited by this paper
• West of Scotland Coronary Prevention Study: identification of high-risk groups and comparison with other cardiovascular intervention trials.

  1996cited by this paper
• FH Afrikaner-3 LDL receptor mutation results in defective LDL receptors and causes a mild form of familial hypercholesterolemia.

  1995cited by this paper
• Nonradioactive multiplex PCR screening strategy for the simultaneous detection of multiple low-density lipoprotein receptor gene mutations.

  1995cited by this paper
• Direct correlation between cholesterol synthesis and hepatic secretion of apolipoprotein B-100 in normolipidemic subjects.

  1995cited by this paper
• Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group.

  1995cited by this paper
• Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia

  1995cited by this paper
• Improved heteroduplex detection of single-base substitutions in PCR-amplified DNA.

  1994cited by this paper
• Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)

  1994cited by this paper
• Correspondence between plasma mevalonic acid levels and deuterium uptake in measuring human cholesterol synthesis

  1992cited by this paper
• Identification and properties of the proline664-leucine mutant LDL receptor in South Africans of Indian origin.

  1992cited by this paper
• Comparative hypolipidemic effects of lovastatin and simvastatin in patients with heterozygous familial hypercholesterolemia.

  1992cited by this paper
• The molecular basis and diagnosis of familial hypercholesterolaemia in South African Afrikaners

  1991cited by this paper
• The effects of simvastatin on plasma lipoproteins and cholesterol homeostasis in patients with heterozygous familial hypercholesterolaemia

  1990cited by this paper
• Increased urinary mevalonic acid excretion in patients with abetalipoproteinemia and homozygous hypobetalipoproteinemia.

  1989cited by this paper
• Reduction in plasma low-density lipoprotein cholesterol and urinary mevalonic acid by lovastatin in patients with heterozygous familial hypercholesterolemia.

  1989cited by this paper
• The Metabolic basis of inherited disease

  1989cited by this paper
• Two common low density lipoprotein receptor gene mutations cause familial hypercholesterolemia in Afrikaners.

  1989cited by this paper
• Contrasting effects of lovastatin and cholestyramine on low-density lipoprotein cholesterol and 24-hour urinary mevalonate excretion in patients with heterozygous familial hypercholesterolemia.

  1989cited by this paper
• Two mutant low-density-lipoprotein receptors in Afrikaners slowly processed to surface forms exhibiting rapid degradation or functional heterogeneity.

  1988cited by this paper
• A receptor-mediated pathway for cholesterol homeostasis.

  1986cited by this paper
• Plasma mevalonate as a measure of cholesterol synthesis in man.

  1984cited by this paper
• Mevalonic acid in human plasma: relationship of concentration and circadian rhythm to cholesterol synthesis rates in man.

  1982cited by this paper
• Metabolism of plasma mevalonate in rats and humans.

  1982cited by this paper
• Cadiovascular complications of homozygous familial hypercholesterolaemia.

  1980cited by this paper
• Multivalent feedback regulation of HMG CoA reductase, a control mechanism coordinating isoprenoid synthesis and cell growth.

  1980cited by this paper
• Metabolic studies in familial hypercholesterolemia. Evidence for a gene-dosage effect in vivo.

  1979cited by this paper
• Elevated cholesterol and bile acid synthesis in a young patient with homozygous familial hypercholesterolemia.

  1979cited by this paper
• Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge.

  1972cited by this paper

• Unveiling Familial Hypercholesterolemia—Review, Cardiovascular Complications, Lipid-Lowering Treatment and Its Efficacy

  2024cites this paper
• [Rationale for Increasing Doses of Statins in Everyday Clinical Practice].

  2024cites this paper
• Familial Hypercholesterolemia: A Literature Review of the Pathophysiology and Current and Novel Treatments

  2023cites this paper
• Familial hypercholesterolemia and its manifestations: Practical considerations for general practitioners.

  2023cites this paper
• Modelling the potential long-term survival benefit of evinacumab treatment versus standard of care in patients with homozygous familial hypercholesterolemia.

  2023cites this paper
• New algorithms for treating homozygous familial hypercholesterolemia

  2022cites this paper
• Advancements in the Treatment of Homozygous Familial Hypercholesterolemia

  2022cites this paper
• Efficacy and Safety of Lomitapide in Homozygous Familial Hypercholesterolaemia: A Systematic Review

  2022cites this paper
• A Comprehensive Review of PCSK9 Inhibitors

  2022cites this paper
• Evinacumab: a new option in the treatment of homozygous familial hypercholesterolemia

  2022cites this paper
• New Frontiers in the Treatment of Homozygous Familial Hypercholesterolemia.

  2021cites this paper
• First Choice Lipid-Lowering Treatment of Hypercholesterolemias

  2021cites this paper
• Evinacumab for Homozygous Familial Hypercholesterolemia.

  2020cites this paper
• Successful pharmacological management of a child with compound heterozygous familial hypercholesterolemia and review of the recent literature.

  2020cites this paper
• Plasma non-cholesterol sterols as markers of cholesterol synthesis and intestinal absorption: a critical review.

  2020cites this paper
• Therapeutic effects of rosuvastatin in hypercholesterolemic prediabetic mice in the absence of low density lipoprotein receptor.

  2019cites this paper
• Review of the scientific evolution of gene therapy for the treatment of homozygous familial hypercholesterolaemia: past, present and future perspectives

  2019cites this paper
• Survival in homozygous familial hypercholesterolaemia is determined by the on-treatment level of serum cholesterol

  2018cites this paper
• Statins and other lipid-lowering therapy and pregnancy outcomes in homozygous familial hypercholesterolaemia: A retrospective review of 39 pregnancies.

  2018cites this paper
• Familial hypercholesterolemia treatments: Guidelines and new therapies.

  2018cites this paper
• Managing Discovery in the Life Sciences: Harnessing Creativity to Drive Biomedical Innovation

  2018cites this paper
• Effect of atorvastatin on testosterone levels.

  2018cites this paper
• Homozygous familial hypercholesterolemia: modern aspects of pathogenesis, diagnostics and treatment

  2018cites this paper
• OBSOLETE: Familial Hypercholesterolemia

  2018cites this paper
• Vaccines Targeting PCSK9: A Promising Alternative to Passive Immunization with Monoclonal Antibodies in the Management of Hyperlipidaemia?

  2018cites this paper
• Gene therapy, a promising treatment for familial hypercholesterolaemia.

  2017cites this paper
• Targeting microsomal triglyceride transfer protein and lipoprotein assembly to treat homozygous familial hypercholesterolemia

  2017cites this paper
• Efficacy of Rosuvastatin in Children With Homozygous Familial Hypercholesterolemia and Association With Underlying Genetic Mutations.

  2017cites this paper
• Epidemiology and management of hyperlipidemia.

  2017cites this paper
• Anti-PCSK9 antibodies for the treatment of heterozygous familial hypercholesterolemia: patient selection and perspectives

  2017cites this paper
• A lipidologist perspective of global lipid guidelines and recommendations, part 1: Lipid treatment targets and risk assessment.

  2016cites this paper
• Familial hypercholesterolemia/autosomal dominant hypercholesterolemia: Molecular defects, the LDL-C continuum, and gradients of phenotypic severity.

  2016cites this paper
• Recent Developments in Gene Therapy for Homozygous Familial Hypercholesterolemia

  2016cites this paper
• Hipercolesterolemia familiar: artículo de revisión

  2016cites this paper
• Evolocumab for the treatment of homozygous familial hypercholesterolaemia

  2016cites this paper
• Effets à long terme de l'atorvastatine à faible dose sur l'athérosclérose : une étude pluridisciplinaire chez un modèle animal, le lapin Watanabe

  2015cites this paper
• Homozigot ailevi hiperkolesterolemi: klinisyenlerin taniyi ve klinik yönetimi gelistirmelerine yönelik yeni anlayislar ve rehberlik. Avrupa Ateroskleroz Dernegi'nin Ailevi Hiperkolesterolemi Üzerine Uzlasi Paneli yazili görüsü.

  2015cites this paper
• [Homozygous familial hypercholesterolaemia: Spanish adaptation of the position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society. Consensus document of the Spanish Society of Arteriosclerosis (SEA) and Familial Hypercholesterolaemia Foundation (

  2015cites this paper
• Hipercolesterolemia familiar homocigota: adaptación a España del documento de posición del grupo de consenso sobre hipercolesterolemia familiar de la Sociedad Europea de Arteriosclerosis. Documento de Consenso de la Sociedad Española de Arteriosclerosis (SEA) y la Fundación Hipercolesterolemia Famil

  2015cites this paper
• The Agenda for Familial Hypercholesterolemia: A Scientific Statement From the American Heart Association.

  2015cites this paper
• National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)

  2015cites this paper
• Lipid-Lowering Therapy and Apheresis: Indications and Outcomes

  2015cites this paper
• Statins and Lomitapide: A Suitable Response for Homozygous Familial Hypercholesterolemia?

  2015cites this paper
• Genetic considerations in the treatment of familial hypercholesterolemia

  2015cites this paper
• [Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society].

  2015cites this paper
• Lomitapide for the management of homozygous familial hypercholesterolemia.

  2014cites this paper
• Current Treatment of Famil ial Hypercholesterolaemia

  2014cites this paper
• Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society

  2014cites this paper
• Familial hypercholesterolemia and estimation of US patients eligible for low-density lipoprotein apheresis after maximally tolerated lipid-lowering therapy.

  2014cites this paper
• Treatment of homozygous familial hypercholesterolemia

  2014cites this paper
• The role of rosuvastatin in the treatment of pediatric homozygous familial hypercholesterolemia

  2014cites this paper
• Current Treatment of Familial Hypercholesterolaemia.

  2014cites this paper
• Novel Therapies for Treating Familial Hypercholesterolemia

  2013cites this paper
• Lomitapide: a guide to its use in adults with homozygous familial hypercholesterolaemia in the EU

  2013cites this paper
• Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study.

  2013cites this paper
• Lomitapide: A Review of its Use in Adults with Homozygous Familial Hypercholesterolemia

  2013cites this paper
• High-Dose Statin Therapy Does Not Induce Insulin Resistance in Patients with Familial Hypercholesterolemia

  2012cites this paper
• Homozygous familial hypercholesterolemia: current perspectives on diagnosis and treatment.

  2012cites this paper
• Severe familial hypercholesterolaemia: current and future management.

  2012cites this paper
• EVIEW evere familial hypercholesterolaemia : Current and uture management ypercholestérolémie familiale sévère : prise en charge actuelle et future

  2012cites this paper
• Atorvastatin

  2012cites this paper
• Lipid lowering efficacy of atorvastatin.

  2012cites this paper
• Targeting the reperfusion injury salvage kinase pathway in the clinical setting

  2011cites this paper
• [Severe hypercholesterolemia in children. Presentation of two cases and update of the literature].

  2011cites this paper
• Failure to recapture cardioprotection with high-dose atorvastatin in coronary artery bypass surgery: a randomised controlled trial Andrew J. LudmanDerek J. HausenloyGirish BabuJonathon Hasleton • Vinod VenugopalEdney Boston-GriffithsJohn YapDavid Lawrence • Martin HaywardShyam KolvekarGiulio Bognolo

  2011cites this paper
• Reduction in Mortality in Subjects With Homozygous Familial Hypercholesterolemia Associated With Advances in Lipid-Lowering Therapy

  2011cites this paper
• Failure to recapture cardioprotection with high-dose atorvastatin in coronary artery bypass surgery: a randomised controlled trial

  2011cites this paper
• [Familial hypercholesterolemia. Contemporary aspects of diagnosis, prevention, and therapy].

  2009cites this paper
• PLEIOTROPIC MECHANISMS OF STATIN ACTION IN ALZHEIMER'S DISEASE

  2008cites this paper
• A dose-titration and comparative study of rosuvastatin and atorvastatin in patients with homozygous familial hypercholesterolaemia.

  2008cites this paper
• Efeito do processo de obtenção do catchup sobre seus compostos antioxidantes, capacidade seqüestrante do radical DPPH e cor

  2008cites this paper
• Drug Therapy for Hypercholesterolemia and Dyslipidemia

  2008cites this paper
• A meta-analysis to evaluate the efficacy of statins in children with familial hypercholesterolemia.

  2007cites this paper
• Time-of-intake (morning versus evening) of extended-release fluvastatin in hyperlipemic patients is without influence on the pharmacodynamics (mevalonic acid excretion) and pharmacokinetics.

  2007cites this paper
• The effect of ezetimibe on serum lipids and lipoproteins in patients with homozygous familial hypercholesterolemia undergoing LDL-apheresis therapy.

  2006cites this paper
• Clinical implications of pharmacogenomics of statin treatment

  2006cites this paper
• Severity of Hyperlipidemia Does Not Affect Antiatherosclerotic Effect of an Angiotensin II Receptor Antagonist in Apolipoprotein E-deficient Mice

  2006cites this paper
• Effects of atorvastatin on lipid metabolism in normolipidemic and hereditary hyperlipidemic, non-laying hens.

  2006cites this paper
• Non-cholesterol sterols in serum, lipoproteins, and red cells in statin-treated FH subjects off and on plant stanol and sterol ester spreads.

  2005cites this paper
• Type IIa Familial Hypercholesterolemia With Hypoplastic Aortic Root

  2004cites this paper
• Non-cholesterol sterols in serum, lipoproteins, and red cells : Effects of dietary phytosterols in familial hypercholesterolemia

  2004cites this paper
• Homozygous Familial Hypercholesterolemia and Its Management

  2004cites this paper
• Statin Induction of Liver Fatty Acid-Binding Protein (L-FABP) Gene Expression Is Peroxisome Proliferator-activated Receptor-α-dependent*

  2004cites this paper
• Simvastatin: a review

  2004cites this paper
• Current management of severe homozygous hypercholesterolaemias

  2004cites this paper
• Avasimibe, an ACAT inhibitor, enhances the lipid lowering effect of atorvastatin in subjects with homozygous familial hypercholesterolemia.

  2003cites this paper
• Lipid-lowering effects of TAK-475, a squalene synthase inhibitor, in animal models of familial hypercholesterolemia.

  2003cites this paper
• Molecular mechanisms of autosomal recessive hypercholesterolemia

  2003cites this paper
• Magnitude of HDL Cholesterol Variation After High-Dose Atorvastatin Is Genetically Determined at the LDL Receptor Locus in Patients With Homozygous Familial Hypercholesterolemia

  2003cites this paper
• [Atorvastatin in the treatment of patients with hereditary hypercholesterolemia].

  2003cites this paper
• Residual effects of lovastatin and simvastatin on urinary mevalonate excretions in patients with familial hypercholesterolemia.

  2003cites this paper
• Long-term (18-month) efficacy of atorvastatin therapy in type 2 diabetics at cardiovascular risk.

  2002cites this paper
• Atorvastatin reduces postprandial accumulation and cholesteryl ester transfer protein-mediated remodeling of triglyceride-rich lipoprotein subspecies in type IIb hyperlipidemia.

  2002cites this paper
• Impact of the characteristics of patients and their clinical management on outcomes in children with homozygous familial hypercholesterolemia

  2002cites this paper
• Autosomal recessive hypercholesterolaemia in Sardinia, Italy, and mutations in ARH: a clinical and molecular genetic analysis.

  2002cites this paper
• Statins in homozygous familial hypercholesterolemia

  2002cites this paper
• Genetic defenses against hypercholesterolemia.

  2002cites this paper
• The effect of atorvastatin on erythrocyte membranes and serum lipids in patients with type-2 hypercholesterolemia

  2002cites this paper
• Feedback inhibition of the cholesterol biosynthetic pathway in patients with Smith-Lemli-Opitz syndrome as demonstrated by urinary mevalonate excretion DOI 10.1194/jlr.M200163-JLR200

  2002cites this paper
• Editorial comment Therapy and clinical trials

  2001cites this paper